CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
Business Wire•24/07/2026•06:26 ET
0
Whiz Insights
CHMP Recommends Gilead’s Trodelvy(® )Plus Keytruda(® )in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
– A Second Approval in First-Line Would Establish Trodelvy as a Backbone Therapy Across PD-L1 Status in the European Union –
Get started
Create a free account to read the full story.